Iceland· IS-EU/1/18/1279/003-004
AMGLIDIA
A glibenclamide product containing glibenclamidum inn, registered in Iceland by AMMTek. The same ATC class is registered in 17 of our 19 countries.
Checked against Icelandic Medicines Agency (Iceland) on
Informational only — not a medical device.
Where it is registered
Glibenclamide is registered in 17 of 19 countries.
Countries holding a registration under ATC A10BB01 (glibenclamide), each read from that country’s own register.
- This record: Iceland, from Icelandic Medicines Agency (Iceland)
- 10 of them publish a price we can compare per daily dose
Glibenclamide · ATC A10BB01
17 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Germany
- Icelandprice
- Ireland
- Italyprice
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of glibenclamide costs, country by country.
Normalised to the WHO defined daily dose (10 mg), the median price runs from $0.19 in France to $0.82 in Switzerland — a ×4.4 gap.
- 3 markets with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Glibenclamide · price per daily dose (10 mg)
USD · FX 28 Sept 2026
- CH Switzerland$0.82
- IT Italy$0.22
- FR France$0.19
The record
At a glance
Icelandic Medicines Agency (Iceland)- Active substance
- Glibenclamidum INN
- Manufacturer
- AMMTek
- Country
- Iceland (IS)
- ATC code
- A10BB01
- ATC class
- Glibenclamide
- Defined daily dose
- 10 mg, O
- Reimbursed
- Not published by this register
- Source register
- Icelandic Medicines Agency (Iceland)
- Last checked
- September 29, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
767 interactions on record for glibenclamide.
Graded by severity as the source publishes them — 21 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Glibenclamide · interactions on record
767 records
- 21 severe
- 472 moderate
- 52 minor
- 222 info
Most severe, free to view
- MiconazoleA07AC01severe
- BosentanC02KX01severe
- Magnesium carbonateA02AA01moderate
- Magnesium oxideA02AA02moderate
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Glibenclamide in 16 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaAMGLIDIAAMMTeK, Paris
- SpainAMGLIDIA 6 mg/ml SUSPENSION ORALAmmtek
- FinlandAMGLIDIAAMMTek
- FranceAMGLIDIA 6 mg/mL, suspension buvableAMMTEK
- IrelandAMGLIDIA 6 mg/mL oral suspensionAMMTek
- NetherlandsAMGLIDIA 6 mg/ml orale suspensieAMMTeK
- PolandAmglidiaAMMTeK
- BelgiumAmglidia 6 mg/mlAMMTeK
Authorised across Europe · EMA
The same active substance is authorised in 12 EEA countries. Names it is sold under:
- Cyprus · Glibesyn, Glitisol
- Germany · Glib-Ratiopharm S, Glibenclamid Abz
- Spain · Glucolón
- France · Daonil, Glibenclamide Arrow
- United Kingdom (Northern Ireland) · Glibenclamide Activase Pharmaceuticals, Glibenclamide Ennogen Ip
- Greece · Asugrin, Deroctyl
- Italy · Gliben, Gliboral
- Liechtenstein · Amglidia
- Malta · Glitisol
- Norway · Amglidia
- Portugal · Glibenclamida Generis
- Romania · Glibenclamidă Arena
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Icelandic Medicines Agency (Iceland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/8c8bdbb9-d2f1-4c23-a774-a5eeb7a76346 GET /v1/drugs/8c8bdbb9-d2f1-4c23-a774-a5eeb7a76346?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Mixtúra, dreifa",
"source": "lyfjastofnun",
"atc_raw": "A10BB01",
"marketed": false,
"strength": "6 mg/ml",
"ma_number": "EU/1/18/1279/003-004",
"substance": "Glibenclamidum INN",
"other_info": "Markaðssetning á Íslandi er háð því að Lyfjastofnun hafi staðfest að sérstök skilyrði er varða öryggi og verkun við notkun lyfsins séu uppfyllt.",
"legal_status": "(R) Lyfseðilsskylt",
"ma_issued_serial": "43244"
}See everything about glibenclamide.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.